Prelude Therapeutics Incorporated

NASDAQ:PRLD

1.27 (USD) • At close November 7, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 0003.4240000000000000000000
Cost of Revenue 00.4520.4260.3310.2790.7230.710.7990.7760.7490.7180.690.6220.4890.44200000000
Gross Profit 0-0.452-0.4263.093-0.279-0.723-0.71-0.799-0.776-0.749-0.718-0.69-0.622-0.489-0.44200000000
Gross Profit Ratio 0000.9030000000000000000000
Reseach & Development Expenses 29.45729.50927.40930.33226.26124.96621.83425.86922.88921.3122.82125.17822.72122.40916.4714.57215.2939.7768.5368.8495.494.974.97
General & Administrative Expenses 7.9197.6556.9347.0477.1247.4327.2817.5167.5178.1517.4677.8328.1155.5135.4974.8742.8511.661.2011.2461.3940.5950.595
Selling & Marketing Expenses 0-0.452000000000000000000000
SG&A 7.9197.2036.9347.0477.1247.4327.2817.5167.5178.1517.4677.8328.1155.5135.4974.8742.8511.661.2011.2461.3940.5950.595
Other Expenses 02.4242.9124.3042.7771.9671.3974.7440.4482.0870.8230.1680.1491.0570.6670.1961.3840.0280.2260.0560.1500
Operating Expenses 37.37636.71234.34337.37933.38532.39829.11533.38530.40629.46130.28833.0130.83627.92221.96719.44618.14411.4369.73710.0956.8845.3995.399
Operating Income -34.376-37.164-34.343-37.379-33.385-32.398-29.115-33.385-30.406-29.461-30.288-33.01-30.836-27.922-21.967-19.446-18.144-11.436-9.737-10.095-6.884-5.565-5.565
Operating Income Ratio 000-10.9170000000000000000000
Total Other Income Expenses Net 2.1052.4242.9124.3042.7771.9671.3974.7440.4482.0870.8230.1680.1491.0570.6670.1961.3840.0280.2260.0560.150.1670.167
Income Before Tax -32.271-34.74-31.431-33.075-30.608-30.431-27.718-28.641-29.958-27.374-29.465-32.842-30.687-26.865-21.3-19.25-16.76-11.408-9.511-10.039-6.734-5.399-5.399
Income Before Tax Ratio 000-9.660000000000000000000
Income Tax Expense 00-0.4261.676-0.2790.239-1.397-7.654-0.448-2.087-0.823-0.168-0.356-0.29-0.28200000000
Net Income -32.271-34.74-31.431-33.075-30.608-30.431-26.321-20.987-29.51-25.287-28.642-32.842-30.687-26.865-21.3-19.25-16.76-11.408-9.511-10.039-6.734-5.399-5.399
Net Income Ratio 000-9.660000000000000000000
EPS -0.43-0.46-0.42-0.48-0.45-0.54-0.55-0.44-0.62-0.53-0.61-0.71-0.66-0.58-0.47-0.51-0.44-0.3-0.29-0.31-0.21-3.43-3.43
EPS Diluted -0.43-0.46-0.42-0.48-0.45-0.54-0.55-0.44-0.62-0.53-0.61-0.71-0.66-0.58-0.47-0.51-0.44-0.3-0.29-0.31-0.21-3.42-3.42
EBITDA -34.376-36.712-34.343-37.048-33.385-32.117-28.837-33.023-30.069-29.143-29.981-32.72-30.57-27.723-21.807-19.313-18.002-11.301-9.605-9.967-6.785-5.488-5.488
EBITDA Ratio 000-10.820000000000000000000